ArticleFrontiers in pharmacology2019
Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
Chan Zou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.